® Omega MonoPure Formulas Blood Sugar Support 3X Greater Absorption* Clinical Applications
»» Positively Affects the Production of Arachidonic Acid-Derived Eicosanoids*
»» Supports Cardiovascular Health* Cardiovascular Support »» Supports Healthy Mental Functioning* »» Supports Healthy Glucose and Insulin Metabolism* »» By Supplying the Precursors EPA and DHA, Helps the Body Generate Specialized Proresolving Lipid Mediators, Such as Resolvins and Protectins*
The Omega MonoPure family of formulas feature IFOS five-star certified MaxSimil® monoglyceride fish oil that has a three times greater EPA+DHA absorption rate than an equivalent dose of other leading fish oils. Through the use of MaxSimil patented lipid absorption enhancement Cytokine Balance Support Omega MonoPure® 1300 EC is available in 60 softgels and 120 softgels technology (PLATform), the fish oil is absorption-ready and can be Omega MonoPure® 650 EC is available in 60 softgels and 120 softgels directly assimilated in the intestinal tract for maximum benefit. Arthricor® ® Omega MonoPure MD EC is available in 60 softgels olive extract, found in Omega MonoPure MD EC, provides additional cardiovascular support.* Discussion MaxSimil® Patented Lipid Absorption Enhancement Technology (PLATform) inhibition and apoptosis in colorectal, breast, lung, and prostate diseased cell The MaxSimil PLATform is a novel monoglyceride delivery system that enhances lines was first demonstrated in a series of in vitro studies.[4-6] Researchers absorption of lipid-based and lipid-soluble nutraceutical and food ingredients. subsequently set out to demonstrate efficacy in animal models after oral This technology has been applied to XYMOGEN’s Omega MonoPure formulas administration. In three separate animal models, MaxSimil EPA and DHA forms in order to create a unique vehicle by which to deliver EPA and DHA. Due to showed superior activity on diseased cell-line growth inhibition and cytokine the fact that monoglyceride oils are intrinsically emulsifiers and are, by nature, production when compared to control, corn oil, krill oil, or the parent forms [4,7,8] in a readily absorbable form (Figure 1), they can bypass the body’s normal fat ethyl ester (EE) EPA and ethyl ester (EE) DHA. These in vivo animal studies Fatty Acids Essential digestion process. These qualities make Omega MonoPure an excellent method proved that orally supplemented MaxSimil EPA and DHA were well-absorbed and for delivering omega-3 fatty acids, especially to individuals with digestive, bioactive. Researchers postulated that the observed superior effects of MaxSimil pancreatic, or gall bladder challenges. Studies show that MaxSimil fish oils (FO) EPA and DHA forms were the result of enhanced absorption, and they set out to have three times (300%) greater absorption of EPA and DHA compared to other prove this hypothesis.* [1-3] leading fish oils.* Preclinical Bioavailability Studies Figure 1. Monoglyceride Chemical Representation in MaxSimil Fish Oils (R1 = fatty acid) The in vivo pharmacokinetic studies in rodents involved a comparison between MaxSimil DHA FO and its parent EE DHA FO and an analysis of blood CH OH concentrations of DHA over time. The doses used were equivalent to human 2 doses of 3 g/day and 30 g/day; the latter was included primarily to investigate toxicity at high doses. Researchers found that MaxSimil DHA FO had a three
times (3x) higher peak concentration (6% versus 2%, Figure 2), a 3x higher Neurologic & Cognitive HC OH saturation potential at the high dose (10% versus 3%), and a 3x higher O absorption rate (at a 3 g/day equivalent human dose) than its parent DHA FO. No toxicity was observed at either dose level.[1,2] This research demonstrated H C O R1 2 superior bioavailability and presumably better exposure of cells to DHA.*
Unique structure: One fatty acid attached to a glycerol backbone provides two polar ends that Figure 2. Preclinical Bioavailability Study in Rodents Demonstrates Superior Peak Concentration, attract water and a non-polar tail end (R1) that attracts fat, thus enabling self-emulsification of the Saturation, and Absorption of MaxSimil DHA FO Versus Its Parent DHA FO Omega MonoPure formulas.
Reprinted with permission from Ingenutra, Inc. Quality a Si il A g E Omega MonoPure formulas are made using proprietary MaxSimil compositions arent A g E containing monoglyceride FO with no additional ingredients, carriers, or a Si il A g E excipients. Each fish-gelatin softgel is enteric-coated, and every batch of fish arent A g E oil is IFOS five-star certified to ensure the world’s highest standards for purity, DHA/TFA (%) potency, and freshness. The fish oil is non-GMO, certified sustainable from Scandinavia, and antibiotic-free. Additionally, it is eco-friendly because the greater absorption of EPA and DHA ultimately means that fewer grams of fish oil need to be harvested for the same benefit.* In Vitro and In Vivo Animal Studies Time (h) The ability of MaxSimil-enhanced EPA and DHA to positively influence growth Data were derived from Ingenutra, Inc.[1,2] Continued on next page
*These statements have not been evaluated by the Food and Drug Administration. XYMOGEN® Exclusive Professional Formulas This product is not intended to diagnose, treat, cure, or prevent any disease. 800-647-6100 | www.xymogen.com Neurologic & Cognitive Essential Fatty Acids Cytokine Balance Support Cardiovascular Support Blood Sugar Support © XYMOGEN data fromthenon-supplemented group,thedatafrom theMaxSimilDHA not supplemented orprovided3g/dayofMaxSimil DHA.Comparedtothe subjected toeightweeksofahigh-fat, high-carbohydratedietwereeither mucin; andCa(2+)hypersensitivity inlungtissues. expression ofCOX-2,NF-kB,cytokines (e.g.,IL-6,IL-8),MUC5AC,and immuneresponse(e.g.,IgE,leukocytes);the MaxSimil FOonairway In vitroandanimalstudieshavedemonstrated thepositiveeffectsof Expanding Research MaxSimil enhancedFO.* completed thestudysawtheiromega-3absorptionenhancedwhentaking one couldanticipateenhancedeffects.Itisnoteworthythatall20adultswho from EEFOgramforgram.Furthermore,asshownintheanimalstudies, studies, anindividualwouldgetmoreEPA andDHAfromMaxSimilFOthan EPA, DHA,andtheirmetabolites.Basedontheresultsofbioavailability up overtimeandremainhighwithsteadilyincreasingexposureofcellsto given adailydose,circulating EPA andDHAlevelscanbeexpectedtoramp 2-3x higherbloodlevelsofEPA andDHAthantheEEFO.Thismeansthat, but italsodemonstratedthatafter24hours,theMaxSimilFOmaintained Not onlydidthisstudyconfirmthebioavailabilityfindingsinanimalstudy, than 3xhigher(P<.0001)forMaxSimilEPA andDHA(MaxSimilFO).* 3x greaterthantheEEform.Likewise,AUCover24hourswasalsomore animal studywasvalidated:theMaxSimilFOinstantaneousabsorption faster, andmaintainedtheirplasmalevelslonger(Figure3).Thefindinginthe EPA andDHAformswere3xhigher, theyreachedmaximumconcentration to EEEPA+DHA, theresultsindicatedthatatpeakconcentration,MaxSimil concentration (aspercent oftotalfattyacids),Cmax,and AUC.Compared EE FOorMaxSimilFO. administered 6g(containing1800mgEPA and1200mgDHA)perdayof in20healthyadultsagedbetween19and71yearswhowere performed A phase1,double-blind,randomized,crossover, pharmacokineticstudywas Clinical BioavailabilityStudy and DHA as Indicated byCmax,and DHAasIndicated Tmax, and AUC Figure 3. Reprinted withpermissionfromIngenutra, Inc.
E A A FA our E A A FA Human Clinical Study Findings Superior HumanClinicalStudy Demonstrate Absorption ofandExposure toEPA Area nder eCurve i e o a i u Concentration a i u Concentration a Si il F a Si il F a Si il F
>3x >3x [3] ParametersstudiedwereplasmaEPA andDHA
p *These statements havenot been evaluatedby the FoodandDrug Administration. This product is notintendedtodiagnose, treat, cure, orprevent any disease. arent F arent F arent F [8-11] All XYMOGEN Inotherresearch, rats ® A C FormulasMeetorExceed cGMPQualityStandards. C a a tyrosol—for maximumbenefit.* Arthricor providesthreepolyphenols—hydroxytyrosol,oleuropein,and have beenshowntoaprotectiveeffectagainstLDLoxidation. 50 mLofoliveoileachday. Phenoliccompounds,asfoundinArthricor, extract dailyprovidesthepolyphenolicbenefitsofeatingfiveolivesor contributors. constituents areprimary health, accepted thattheMediterraneandietisbeneficialtocardiovascular FO combinedwith50mgofArthricoroliveleafextract.Itisgenerally Each softgelofOmegaMonoPureMDECprovides500mgMaxSimil Arthricor metabolites.* of EPA andDHAaswelltheexpecteddesirablebenefitsoftheir pharmaceutical model,OmegaMonoPurefishoilsprovideallthebenefits than supplyingasinglemoleculeormetabolite,whichwouldmirrorthe body’s “clean-up”responsetothearachidonicacidcascade. through enzymaticconversionofEPA andDHA.Thesemediatorsaidthe and maresins,areEPA andDHAmetabolitesnaturallyproducedinvivo Specialized proresolvinglipidmediators,suchasresolvins,protectins, A NoteAboutResolvinsandOtherEPA andDHAMetabolites D3 metabolites.* in aortictissue,whichcorrelatedwiththeproductionofresolvinD2and lipid levels,cytokineproduction,aorticwallthickness,andaDHA:AAratio health parameters.Measuresincludedbloodpressure,heartrate,serum supplemented groupclearlyshowedapositiveimpactoncardiovascular http://www.ifosprogram.com/consumer-reports.aspx Third-Party CertificateofAnalysis(COA) canbefoundbyvisiting: artificial preservatives. modified organisms(GMOs), artificialcolors, sweeteners, artificial or shellfish, peanuts, treenuts, egg, ingredientsderived fromgenetically DOES NOT CONTAIN: STORAGE: healthcare practitioner. Donotuseiftampersealisdamaged. shoulddiscusspotentialinteractionswith their thinners orothermedication Consult yourhealthcarepractitionerpriortouse. Individualstakingblood practitioner. DIRECTIONS: Omega MonoPure patents 2672513and 2677670. Ingenutra Inc.Protected underUSpatents8,119,690and 8,198,324;Canadian Manufactured usingMaxSimil gelatin]). Contains: stearic acid,andammoniumhydroxide),mixednaturaltocopherols. (ethylcellulose, sodiumalginate,purifiedwater, medium-chaintriglycerides,oleicacid,vegetable Other Ingredients: ** DailyValue notestablished. † DHA(docosahexaenoicacid) EPA (eicosapentaenoicacid) Total Omega-3FattyAcids MaxSimil Total Fat Calories Serving Size:1Softgel Serving Percent DailyValue basedona2,000caloriediet. [14-16] ® Fish(anchovyand/orsardine[sources offishoil],tilapiaand/orpangasius[sources offish FishOilConcentrate ® : OmegaMonoPureMDEC Keeptightlyclosed inacool, placeoutofreachchildren. dry andresearch suggeststhatoliveoilanditsphenolic
Take onesoftgeldaily, oruseasdirectedbyyourhealthcare Softgel(fishgelatin,vegetableglycerin,andpurifiedwater),GRASentericcoating [12] ® 1300ECSupplementFacts Wheat, gluten, corn, yeast, protein, soy products, dairy ® fishoil.MaxSimil
[17-21] Taking Arthricoroliveleaf ® isaregisteredtrademarkof Amount PerServing Continued onnext page
260 mg 600 mg 860 mg 1.3 g 1 g 10 [13]
Rather %Daily Value [19,22,23]
1% ** ** ** *
† Neurologic & Cognitive Essential Fatty Acids Cytokine Balance Support Cardiovascular Support Blood Sugar Support http://www.ifosprogram.com/consumer-reports.aspx Third-Party CertificateofAnalysis(COA) canbefoundbyvisiting: © XYMOGEN Arthricor isatrademark ofEight-IP. patents 2672513and 2677670. Ingenutra Inc.ProtectedunderUSpatents 8,119,690and8,198,324;Canadian Manufactured usingMaxSimil Omega MonoPure http://www.ifosprogram.com/consumer-reports.aspx Third-Party CertificateofAnalysis(COA) canbefoundbyvisiting: (GMOs), artificialcolors, sweeteners, artificial orartificial preservatives. peanuts, treenuts, egg, ingredientsderivedfromgenetically modifiedorganisms DOES NOT CONTAIN: STORAGE: practitioner. Donotuseiftampersealisdamaged. shoulddiscusspotentialinteractionswiththeirhealthcare or othermedication Consult yourhealthcarepractitionerpriortouse. Individualstakingbloodthinners practitioner. DIRECTIONS: Omega MonoPure organisms (GMOs), artificial colors, sweeteners, artificial or artificial preservatives. shellfish, peanuts, treenuts, egg, ingredientsderivedfromgeneticallymodified DOES NOT CONTAIN: STORAGE: practitioner. Donotuseiftampersealisdamaged. shoulddiscusspotentialinteractionswiththeirhealthcare or othermedication Consult yourhealthcarepractitionerpriortouse. Individualstakingbloodthinners practitioner. DIRECTIONS: patents 2672513and2677670. Ingenutra Inc.ProtectedunderUSpatents8,119,690and8,198,324;Canadian Manufactured usingMaxSimil Total Omega-3FattyAcids MaxSimil Total Fat Calories gelatin]). Contains: and ammoniumhydroxide),beeswax,sunflowerlecithin,maltodextrin,silica,mixednaturaltocopherols. (ethylcellulose, sodiumalginate,purifiedwater, medium-chaintriglycerides,oleicacid,vegetablestearic hydroxytyrosol, 4%oleuropein,1%tyrosol) Arthricor DHA(docosahexaenoicacid) EPA (eicosapentaenoicacid) Other Ingredients: ** DailyValue notestablished. † Serving Size:1Softgel Serving MaxSimil Total Fat Calories gelatin]). Contains: acid, andammoniumhydroxide),mixednaturaltocopherols. (ethylcellulose, sodiumalginate,purifiedwater, medium-chaintriglycerides,oleicacid,vegetablestearic Other Ingredients: ** DailyValue notestablished. † DHA(docosahexaenoicacid) EPA (eicosapentaenoicacid) Total Omega-3FattyAcids Serving Size:1Softgel Serving Percent DailyValue basedona2,000caloriediet. Percent DailyValue basedona2,000caloriediet. ® ® ® Fish(anchovyand/orsardine[sources offishoil],tilapiaand/orpangasius[sources offish Fish(anchovyand/orsardine[sources offishoil],tilapia and/orpangasius[sources offish OliveExtract( FishOilConcentrate FishOilConcentrate Keeptightlyclosed inacool, placeoutofreachchildren. dry Keeptightlyclosed inacool, placeoutofreachchildren. dry
Take onesoftgeldaily, oruseasdirectedbyyourhealthcare Take onesoftgeldaily, oruseasdirectedbyyourhealthcare Softgel (tilapia fish gelatin, vegetable glycerin, and purified water), GRAS enteric coating Softgel(tilapiafishgelatin,vegetableglycerin,andpurifiedwater),GRASentericcoating Softgel(fishgelatin,vegetableglycerin,andpurifiedwater),GRASentericcoating ® ® Olea europaea MDECSupplementFacts 650ECSupplementFacts Wheat, gluten, yeast, protein, soy products, dairy shellfish, Wheat, gluten, corn, yeast, protein, soy products, dairy ® ® fishoil.MaxSimil fishoil.MaxSimil )(leaves) (9%
*These statements havenot been evaluatedby the FoodandDrug Administration. ® ® isaregisteredtrademarkof isaregisteredtrademarkof This product is notintendedtodiagnose, treat, cure, orprevent any disease.
Amount PerServing Amount PerServing All XYMOGEN 330 mg 500 mg 100 mg 230 mg 650 mg 300 mg 430 mg 130 mg 50 mg 0.5 g 0.5 g 5 5 ® FormulasMeetorExceed cGMPQualityStandards.
%Daily Value %Daily Value 1% 1% ** ** ** ** ** ** **
* * † † 11. 10. 9. 8. 7. 6. 5. 4. 3. 2. 1. References 23. 22. 21. 20. 19. 18. 17. 16. 15. 14. 13. 12.
inflammation and prevent rho-kinase activation inanallergicmodelofasthma. andpreventrho-kinaseactivation inflammation Morin C, Fortin S, RousseauÉ. reduceairway Newomega-3derivatives Oct;53(4):574-83. [PMID: 25781052] to modelsrelated cystic fibrosis.inflammatory Morin C, Cantin AM, RousseauÉ, etal. Pro-resolvingactionofMAG-DHAinlung 23957343] allergic modelofasthma. Morin C, Fortin S, Cantin AM, etal. MAG-EPA inan resolveslunginflammation J RespirCellMolBiol of17kDinasthma.protein forheterotrimericmyosinlightchainphosphatase andhyperreactivityinlung:inflammation ofPKC-Potentiated inhibitory implication Morin C, Fortin S, Cantin AM, etal. prevents Docosahexaenoicacidderivative 29;17:142. [PMID: 26022389] arthritismodel. inarheumatoid resolve inflammation monoglycerides aremorepotentthandocosahexaenoicacidmonoglycerideto Morin C, BlierPU, Fortin S. acid acidanddocosapentaenoic Eicosapentaenoic 8,329,747.patent December11, 2012. acidmonoglycerides, fatty Polyunsaturated derivatives, andusesthereof. US Fortin S, inventor;CentredeRecherchesurlesBiotechnologiesMarines, assignee. 8,119,690.patent February 21, 2012. acidmonoglycerides, fatty Polyunsaturated derivatives, andusesthereof. US Fortin S, inventor;CentredeRecherchesurlesBiotechnologiesMarines, assignee. Fatty Acids Essent acid monoacylglyceride incolorectalcarcinomacells. Morin C, RousseauÉ, Fortin S. effectsofanewdocosapentaenoic Anti-proliferative internal data] 3020 Omega-3. Sherbrooke(Québec), Canada: Ingenutra;2015. [Unpublished, MaxSimil Patented Lipid Absorption Technology Report: ClinicalStudy MaxSimil thereof andusesthereof. 8,198,324. USpatent June12, 2012. acidmonoglyceridesorderivatives fatty Compositions comprisingpolyunsaturated Fortin S, inventor;CentredeRecherchesurlesBiotechnologiesMarines, assignee. Unpublished, internaldata. Ingenutra. Vitam NutrRes Raederstorff D. Antioxidant activityofolivepolyphenolsin humans: areview. Int May;95(5):1238-44. [PMID: 22440854] productsinvivohumans.expression anditsdownstream ofCD40-ligand withadownregulation by oliveoilpolyphenolsisassociated Castañer O, CovasMI, KhymenetsO, etal. ProtectionofLDLfromoxidation 13;12:78. [PMID: 24886626] cardiovascular diseaseandmortalityinthePREDIMEDStudy. Guasch-Ferré M, HuFB, Martínez-GonzálezMA, etal. Oliveoilintakeand riskof 16488419] effects ofextravirginoliveoil. Bogani P, GalliC, Villa M, etal. andantioxidant Postprandial anti-inflammatory 17617938] randomized crossovercontrolledtrial. Br densitylipoproteinafteroliveoilconsumptioninmen.phenolic contentoflow A Gimeno E, dela Torre-Carbot K, RM, Lamuela-Raventós etal. Changesinthe Am JClinNutr improves thepostprandialprothromboticprofileinhypercholesterolemicpatients. Ruano J, López-MirandaJ, dela Torre R, etal. Intakeofphenol-richvirginoliveoil Clin Nutr diseasepatients:in stablecoronary arandomized, crossover, controlledtrial. Fitó M, CladellasM, dela Torre R, etal. effectofvirginoliveoil Anti-inflammatory 2014 Oct;16(10):446. [PMID: 25115436] Mediterranean dietinpreventionofcardiovasculardisease. Chiva-Blanch G, BadimonL, EstruchR. evidenceoftheeffects Latest disease, shows. study Mayor S. Mediterraneandietreducescardiovasculareventsinpeople withheart 4;368(14):1279-90. [PMID: 23432189] cardiovascular diseasewithaMediterraneandiet. Guasch-Ferré M, HuFB, Martínez-GonzálezMA, etal. preventionof Primary OtherLipidMediat Prostaglandins mediators: anunderstandingofresolvinandprotectinformation. towards Weylandt KH, ChiuCY, GomolkaB, etal. acidsandtheirlipid Omega-3fatty J PhysiolHeartCirc monoacylglyceride onsystemichypertensionandcardiovasculardysfunction. Morin C, RousseauE, BlierPU, etal. Effectofdocosahexaenoicacid Aller Ther . 2008 Apr;62(4):570-74. [PMID: 17375118] . 2012;3(S1):003. doi:10.4172/2155-6121.S1-003. Additional referencesavailable uponrequest . 2007 Aug;86(2):341-46. [PMID: 17684203] . 2009May;79(3):152-65. [PMID: 20209466] . 2013Sep;89(4):203-13. [PMID: 23932824] . 2011 Aug;45(2):366-75. [PMID: 21057106] BMJ Clin Exp Allergy Clin . 2016 24;353:i2348.Apr [PMID: 27114468] . 2015Jul1;309(1):H93-H102. [PMID: 25910811] Atherosclerosis . 2012Mar;97(3-4):73-82. [PMID: 22326554]
J Nutr. . 2013Sep;43(9):1071-82. [PMID: . 2007Jan;190(1):181-86. [PMID: Am JRespirCellMolBiol 2007Dec;98(6):1243-50. [PMID: N EnglJMed Arthritis Res Ther Arthritis Prostaglandins Leukot Prostaglandins Curr Atheroscler Rep Curr Atheroscler Am JClinNutr BMC Med . 2013 Apr .2013 Apr Rev. 08/29/18 . 2015May . 2014May . 2015 DRS-308 . 2012 Eur J Am Am ® J J
.